Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Prevalence of peripheral arterial disease among individuals with type 2 diabetes mellitus in India - A systematic review and meta-analysis","authors":"Esha Arora ,&nbsp;Raja Regan ,&nbsp;Vyshak Uddur Surendra ,&nbsp;Ashokan Arumugam","doi":"10.1016/j.dsx.2024.103124","DOIUrl":"10.1016/j.dsx.2024.103124","url":null,"abstract":"<div><h3>Background</h3><div>Peripheral arterial disease (PAD) is a prevalent complication of type 2 diabetes mellitus (T2DM). As India ranks second in the population afflicted by T2DM, and the objective of this systematic review was to estimate the pooled prevalence of PAD in individuals living with T2DM in India.</div></div><div><h3>Methods</h3><div>Five databases (Cochrane (CENTRAL), MEDLINE (via PubMed), CINAHL (via EBSCO), PEDro, and Scopus) were searched using database-specific search terms from inception to August 2023. Inclusion criteria included studies reporting the prevalence of PAD in Indian adults diagnosed with T2DM of either or both sexes, employing ankle brachial index measurements with a Doppler test or sphygmomanometer. The risk of bias was evaluated using the JBI checklist, and the certainty of evidence was determined via the GRADE approach.</div></div><div><h3>Results</h3><div>Twenty-three articles met the inclusion criteria which comprised of 196,883 individuals with T2DM aged between 30 and 70 years from nine states and one union territory. Utilizing a random effects model, the meta-analysis revealed that the pooled prevalence of PAD among individuals with T2DM in India was 18 % (95 % confidence interval: 10–28 %), with statistically significant heterogeneity observed between studies (I² = 100 %, P &lt; 0.001). Overall certainty in the evidence was low.</div></div><div><h3>Conclusion</h3><div>The combined prevalence of PAD among individuals with T2DM in India is 18 %, indicating a significant portion of the Indian population has been affected. Epidemiological studies utilizing precise assessment tools can enhance the early detection and prevention of PAD in T2DM and improve the certainty of findings.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103124"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual cereals intake is associated with progression of diabetes and diabetic chronic complications","authors":"Siying Tang ,&nbsp;Wenjin Luo ,&nbsp;Ting Li ,&nbsp;Xiangjun Chen ,&nbsp;Qinglian Zeng ,&nbsp;Rufei Gao ,&nbsp;Bing Kang ,&nbsp;Chuan Peng ,&nbsp;Zhihong Wang ,&nbsp;Shumin Yang ,&nbsp;Qifu Li ,&nbsp;Jinbo Hu","doi":"10.1016/j.dsx.2024.103127","DOIUrl":"10.1016/j.dsx.2024.103127","url":null,"abstract":"<div><h3>Background and aims</h3><div>The relationship between cereals intake and diabetes is unclear. We aimed to explore associations between individual cereals intake and risks of incident and progression of diabetes.</div></div><div><h3>Methods</h3><div>We included 502,490 participants from UK Biobank at baseline. A single touchscreen food frequency questionnaire was used to estimate the intake of individual cereals (bran, biscuit, oat, muesli, and other cereals). Main outcomes included incident diabetes and diabetic complications of cardiovascular disease (CVD), chronic kidney disease (CKD) and diabetic retinopathy (DR). Polygenic risk score (PRS) of glycosylated hemoglobin (HbA1c) was calculated for mediating effects analysis.</div></div><div><h3>Results</h3><div>Among participants without diabetes, when compared to subjects who never had cereals, hazard ratios (95%CI) of developing diabetes in those who had ≥6 bowls/week were 0.72 (0.67–0.78) for bran, 0.86 (0.81–0.92) for biscuit, 0.75(0.66–0.84) for oat, and 0.57(0.53,0.61) for muesli. Among people with diabetes without CVD, a higher intake of aforementioned four individual cereals was associated with a 13%–32 % lower risk of developing CVD. Among people with diabetes without CKD, a higher intake of aforementioned four individual cereals was associated with a 9%–28 % lower risk of developing CKD. We observed a significant mediating effect of the PRS of HbA1c for the association between aforementioned four individual cereals and developing diabetes.</div></div><div><h3>Conclusion</h3><div>A higher consumption of cereals was significantly associated with lower risks of diabetes and diabetic complications. Polygenic of HbA1c mediates the effect of cereals on incident diabetes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103127"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial","authors":"Xuan Wang ,&nbsp;Lu Lyu ,&nbsp;Wei Li ,&nbsp;Lingling Xu ,&nbsp;Huabing Zhang ,&nbsp;Shitian Wang ,&nbsp;Yiwen Liu ,&nbsp;Fan Ping ,&nbsp;Yuxiu Li","doi":"10.1016/j.dsx.2024.103126","DOIUrl":"10.1016/j.dsx.2024.103126","url":null,"abstract":"<div><h3>Objective</h3><div>This investigation aimed to evaluate the efficacy and safety of rosuvastatin in treating moderate to severe metabolic associated fatty liver disease (MAFLD).</div></div><div><h3>Methods</h3><div>This prospective, open-label, randomized study included non-diabetic participants with metabolic syndrome and intrahepatocellular lipid (IHCL) levels &gt;10 %, as determined by proton magnetic resonance spectroscopy (¹H-MRS). The primary objective was the effect of a 52-week rosuvastatin treatment (10 mg/day) on IHCL content. Secondary objectives included the association between IHCL reduction and lipid metabolism parameters, along with safety indices such as glycemic control and hepatic and renal function<del>.</del></div></div><div><h3>Results</h3><div>Thirty-two participants completed the study. Rosuvastatin resulted in a significant absolute (△IHCL: 7.61 ± 4.51 vs. 1.54 ± 5.33, p = 0.002) and relative reduction in IHCL (△IHCL%: −42.28 ± 24.90 % vs. −8.91 ± 31.93 %, p = 0.003) compared to the control. Reduction in IHCL correlated significantly with decreases in low-density lipoprotein cholesterol (LDL-C) (r = 0.574, p &lt; 0.01), apolipoprotein B (ApoB) (r = 0.660, p &lt; 0.001), and free fatty acids (FFA) (r = 0.563, p = 0.005). No significant safety differences were observed between groups.</div></div><div><h3>Conclusions</h3><div>Rosuvastatin significantly reduced hepatic steatosis in individuals with moderate to severe MAFLD and metabolic syndrome over 52 weeks, while maintaining a favorable safety profile.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103126"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic outcomes in offspring of women treated with metformin versus insulin for gestational diabetes: A Systematic Review and meta-analysis","authors":"Dimple Rawat ,&nbsp;Yashdeep Gupta ,&nbsp;Arun Kumar Yadav ,&nbsp;Manoj Kumar Tembhre ,&nbsp;Priyanka Das ,&nbsp;Saisree Bakkireddy ,&nbsp;Neeta Singh ,&nbsp;K Aparna Sharma ,&nbsp;Rinchen Zangmo ,&nbsp;Avdhesh Chandra ,&nbsp;Ashish Datt Upadhyay ,&nbsp;Deepali Garg","doi":"10.1016/j.dsx.2024.103134","DOIUrl":"10.1016/j.dsx.2024.103134","url":null,"abstract":"<div><h3>Introduction</h3><div>Gestational diabetes mellitus (GDM) is commonly managed with either metformin or insulin, but their comparative effects on offspring cardiometabolic outcomes are not fully understood.</div></div><div><h3>Objective</h3><div>To investigate the impact of metformin and insulin, two distinct pharmacological interventions, on cardiometabolic outcomes in offspring of mothers with GDM.</div></div><div><h3>Methodology</h3><div>Systematic literature review was performed for articles (randomized control trials) published from 1974 to May 2024 using a predefined search strategy. Studies were screened for title and abstract followed by full text. Quality assessment was done using a separate risk of bias tool in line with the PRISMA-2020 checklist.</div></div><div><h3>Results</h3><div>Among 5463 records, five studies (metformin = 409 children or insulin n = 434 children) were included. Offspring of metformin-treated mothers in the age range of 5–9 years had more fat-free mass (kg) by bioimpedance and abdominal (subcutaneous and visceral) fat volume (cm³) by MRI. Fasting plasma glucose and triglycerides were lower in the metformin-treated group for offspring aged 5–9 years. No significant differences were observed for other cardiometabolic outcomes. Limited data available for offsprings less than 5 years of age precluded meta-analysis for the available outcomes, except for body weight, and difference for this was also not significant.</div></div><div><h3>Conclusion</h3><div>In short term no major differences has been seen in most of the cardiometabolic outcomes evaluated in the meta-analysis. Future trials with longer follow up are required and in different ethnicities.</div></div><div><h3>Systematic review registration</h3><div>PROSPERO-CRD42023450990.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103134"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning and statistical models to predict all-cause mortality in type 2 diabetes: Results from the UK Biobank study","authors":"Tingjing Zhang ,&nbsp;Mingyu Huang ,&nbsp;Liangkai Chen ,&nbsp;Yang Xia ,&nbsp;Weiqing Min ,&nbsp;Shuqiang Jiang","doi":"10.1016/j.dsx.2024.103135","DOIUrl":"10.1016/j.dsx.2024.103135","url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to compare the performance of contemporary machine learning models with statistical models in predicting all-cause mortality in patients with type 2 diabetes mellitus and to develop a user-friendly mortality risk prediction tool.</div></div><div><h3>Methods</h3><div>A prospective cohort study was conducted including 22,579 people with diabetes from the UK Biobank. Models evaluated include Cox proportional hazards, random survival forests (RSF), gradient boosting (GB) survival, DeepSurv, and DeepHit.</div></div><div><h3>Results</h3><div>Over a median follow-up period of 9 years, 2,665 patients died. Machine learning models outperformed the Cox model in the validation dataset, with C-index values of 0.72–0.73 vs. 0.71 for Cox (p &lt; 0.01). Deep learning models, particularly DeepHit, demonstrated superior calibration and achieved lower Brier scores (0.09 vs. 0.10 for Cox, p &lt; 0.05). An online prediction tool based on the DeepHit was developed for patient care: <span><span>http://123.57.42.89:6006/</span><svg><path></path></svg></span>.</div></div><div><h3>Conclusions</h3><div>Machine learning models performed better than statistical models, highlighting the potential of machine learning techniques for predicting all-cause mortality risk and facilitating personalized healthcare management for individuals with diabetes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103135"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of Bacillus Calmette-Guerin (BCG) vaccine intervention for patients with Type 1 Diabetes (T1D): A systematic review and meta-analysis","authors":"Sunil B. Korde ,&nbsp;Smita R. Pillewan ,&nbsp;Sanket R. Dumbre ,&nbsp;Anjali R. Bandgar ,&nbsp;Prajakta S. Shinde ,&nbsp;Sunil Gairola ,&nbsp;Vandana S. Nikam","doi":"10.1016/j.dsx.2024.103102","DOIUrl":"10.1016/j.dsx.2024.103102","url":null,"abstract":"<div><h3>Purpose</h3><p>Immunotherapy is an emerging therapeutic modality for many autoimmune, oncology, and infectious diseases to cure or prevent the underlying causes. Several immunotherapeutic agents are investigated for their beneficial potential in patients with diabetes. However, none have culminated into a successful therapy. The present comprehensive meta-analysis and systematic review covers the last two decades of historical research evaluating the Bacillus Calmette-Guerin (BCG) vaccine as an immunotherapeutic agent in diabetes, along with updated information on similar recent publications.</p></div><div><h3>Method</h3><p>A total of 278 articles were retrieved through literature databases, and after applying inclusion and exclusion criteria as per PRISMA guidelines, seven studies were selected for meta-analysis using Cochrane Q statistics.</p></div><div><h3>Results</h3><p>Our meta-analysis revealed marginal benefits, lowering glycosylated/glycated haemoglobin (HbA1C) levels and glutamic-acid-decarboxylase (GAD) autoantibodies in BCG treated people with Type 1 Diabetes (T1D) compared to the matched control individuals. The BCG intervention found to be ineffective in regulating C-peptide (connecting peptide) and clinical remission (CR) i.e. improved glycemic regulation, though beneficial tendency was observed.</p></div><div><h3>Conclusion</h3><p>Our systematic review and meta-analysis revealed benefits of BCG vaccine intervention in T1D patients, including improved HbA1C and GAD autoantibody levels. However, the study has several limitations stemming from BCG vaccine-related factors and patient characteristics. Therefore, a large clinical trial with an enhanced study design is needed to validate the immunity-related benefits of the BCG vaccine for glucose metabolism in patients with T1D.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103102"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity prediction: Novel machine learning insights into waist circumference accuracy","authors":"Carl Harris ,&nbsp;Daniel Olshvang ,&nbsp;Rama Chellappa ,&nbsp;Prasanna Santhanam","doi":"10.1016/j.dsx.2024.103113","DOIUrl":"10.1016/j.dsx.2024.103113","url":null,"abstract":"<div><h3>Aims</h3><p>This study aims to enhance the precision of obesity risk assessments by improving the accuracy of waist circumference predictions using machine learning techniques.</p></div><div><h3>Methods</h3><p>We utilized data from the NHANES and Look AHEAD studies, applying machine learning algorithms augmented with uncertainty quantification. Our approach centered on conformal prediction techniques, which provide a methodological basis for generating prediction intervals that reflect uncertainty levels. This method allows for constructing intervals expected to contain the true waist circumference values with a high degree of probability.</p></div><div><h3>Results</h3><p>The application of conformal predictions yielded high coverage rates, achieving 0.955 for men and 0.954 for women in the NHANES dataset. These rates surpassed the expected performance benchmarks and demonstrated robustness when applied to the Look AHEAD dataset, maintaining coverage rates of 0.951 for men and 0.952 for women. Traditional point prediction models did not show such high consistency or reliability.</p></div><div><h3>Conclusions</h3><p>The findings support the integration of waist circumference into standard clinical practice for obesity-related risk assessments using machine learning approaches.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103113"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of food-based dietary strategies on achieving type 2 diabetes remission: A systematic review","authors":"Hadis Mozaffari ,&nbsp;Rana Madani Civi ,&nbsp;Mohammadreza Askari ,&nbsp;Clover Lee ,&nbsp;Emily Wong ,&nbsp;Cheryl Wong ,&nbsp;Annalijn I. Conklin","doi":"10.1016/j.dsx.2024.103096","DOIUrl":"10.1016/j.dsx.2024.103096","url":null,"abstract":"<div><h3>Objective</h3><p>Conventional wisdom once asserted that diabetes was irreversible. However, contemporary research indicates that dietary changes may contribute to achieving diabetes remission in persons with type 2 diabetes (T2D). We aimed to determine the effectiveness of food-based dietary approaches for T2D remission.</p></div><div><h3>Methods</h3><p>We systematically searched Medline, EMBASE, and Web of Science, along with exploring grey literature, to identify longitudinal studies. Data extraction and quality assessment adhered to predetermined criteria, and the results of the included studies were analyzed using a narrative synthesis and graphical display.</p></div><div><h3>Results</h3><p>We included 52 original studies—40 % were rated as low-risk of bias. Overall, studies showed the low-carbohydrate Mediterranean diet (LCMD), compared to a low-fat diet, was more effective for achieving T2D remission in newly diagnosed patients who also had a weight loss of up to 6 kg. Compared to both the traditional Mediterranean diet and the American Diabetic Association diet, the LCMD was also more effective at diabetes remission for persons with T2D with any duration of diabetes; however, more substantial weight loss of 8 kg was required. Other diets that appeared effective for T2D remission included low-calorie diets and diets high in plant protein sources. Less weight loss was needed to achieve remission on plant-based diets than a low-calorie diet and low-carbohydrate diet.</p></div><div><h3>Conclusions</h3><p>Diets high in plant protein sources may support T2D remission, particularly among newly diagnosed patients. For patients with a duration of over 2 years, the combination of plant-based diets with greater weight loss should be considered to induce remission.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103096"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001577/pdfft?md5=359f3ac34ff902389067b31cf5cd1956&pid=1-s2.0-S1871402124001577-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early detection of altered cold perception in elderly with type 2 diabetes using a novel Quantitative Sensory Testing method","authors":"Louise Trocmet ,&nbsp;André Dufour ,&nbsp;Thierry Pebayle ,&nbsp;Olivier Després ,&nbsp;Ségolène Lithfous","doi":"10.1016/j.dsx.2024.103097","DOIUrl":"10.1016/j.dsx.2024.103097","url":null,"abstract":"<div><h3>Aim</h3><p>To compare the effectiveness of two methods for measuring cold detection thresholds in screening for temperature-perception deficits in elderly individuals with type 2 diabetes (T2 diabetes).</p></div><div><h3>Methods</h3><p>Cold threshold measurements were performed on seven body regions of participants with diabetes without neuropathy (n = 30; mean age, 70.9 ± 6.5 years) and healthy participants (n = 73; mean age, 68 ± 5 years). Two protocols applying the Levels Method were used: the first used skin temperature as the starting point; the second used 40 °C.</p></div><div><h3>Results</h3><p>Cold detection thresholds were significantly higher in subjects with diabetes, particularly on the foot. For CDT TSk, values were −2.22 ± 1.91 °C in non-diabetic and −3.27 ± 3.33 °C in diabetic groups (p = 0.023); for CDT 40, values were −9.82 ± 3.5 °C and −12.18 ± 4.5 °C (p = 0.003). However, after adjusting for age, the group effect on cold threshold with skin temperature as baseline disappeared. Sensory screens showed that the Area Under Curve of the method using a 40 °C baseline was 0.69 (p = 0.002).</p></div><div><h3>Conclusion</h3><p>Measuring the cold detection threshold on the foot with a 40 °C baseline is more effective than using skin temperature as a baseline for screening sensory alterations in elderly subjects with type 2 diabetes before neuropathy onset.</p></div><div><h3>Significance</h3><p>These findings highlight the importance of selecting the appropriate cold detection threshold method for elderly individuals with type 2 diabetes. The optimal method can facilitate early identification of sensory changes, minimizing complications and improving overall well-being.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103097"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trabecular and cortical bone microarchitecture using high-resolution peripheral quantitative computed tomographic imaging in diabetic peripheral neuropathy","authors":"Durairaj Arjunan,&nbsp;Ashu Rastogi,&nbsp;Jayaditya Ghosh,&nbsp;Soham Mukherjee,&nbsp;Raveena Singh,&nbsp;Vandana Dhiman,&nbsp;Sanjay K. Bhadada","doi":"10.1016/j.dsx.2024.103109","DOIUrl":"10.1016/j.dsx.2024.103109","url":null,"abstract":"<div><h3>Context</h3><p>Type 2 Diabetes Mellitus (T2D) is associated with an increased risk of fragility fracture despite normal areal bone mineral density (BMD). The contribution of diabetic peripheral neuropathy (PN) to volumetric BMD (vBMD) and bone microarchitecture in T2D is not explored.</p></div><div><h3>Objective</h3><p>To assess vBMD and microarchitectural properties of bone using high-resolution peripheral quantitative computed tomography (HR-pQCT) in patients of T2D with or without PN.</p></div><div><h3>Design</h3><p>This is a cross-sectional study of patients of T2D divided into two groups [patients with T2D without PN (Group A) and T2D with PN (Group B)]. All patients underwent clinical examination, biochemical evaluation, dual-energy X-ray absorptiometry (DXA), and HR-pQCT of the radius and tibia.</p></div><div><h3>Results</h3><p>A total of 296 patients were included in the study [Group A (n = 98), Group B (n = 198)]. HR-pQCT demonstrated a significant difference in total vBMD[mg/cm³] at tibia (291.6 ± 61.8 vs. 268.2 ± 63.0; p-0.003); cortical vBMD[mg/cm³] at tibia [912.5 (863.3, 962.4) vs. 853.8 (795.3, 913.2) p-0.000], among groups A and B respectively. Among the microarchitecture parameters, there was a significant difference in cortical porosity at the tibia (2.5% ±1.7% vs. 3%±1.7%; p-0.004), trabecular number[mm^-1] at the tibia [1.080 (0.896, 1.237) vs. 1.140 (0.983, 1.286), p-0.045] and trabecular thickness[mm] at the radius [0.228 (0.217, 0.247) Vs. 0.238 (0.224, 0.253); p-0.006], among groups A and B respectively.</p></div><div><h3>Conclusion</h3><p>Despite comparable areal BMD, T2D patients with PN have diminished vBMD and deteriorated skeletal microarchitecture, compared to those without PN.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 8","pages":"Article 103109"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142077268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}